Weight Management and GLP-1 Care in a DPC in 2027 (Labels, Compounding and Coverage)

Can a DPC practice prescribe GLP-1s for weight management in 2027?

Yes. A licensed clinician in a direct primary care practice can prescribe FDA-approved GLP-1 medicines for weight management within the label and state practice rules, and the membership changes how the care is paid for, not what the prescribing rules are. As of November 5, 2026, FDA's shortage data lists no shortage of semaglutide injection or tirzepatide, which leaves compounded copies of those drugs tightly restricted. For Medicare patients, weight-management use runs through a temporary CMS program called the Medicare GLP-1 Bridge, which lasts through December 31, 2027 and excludes patients with type 2 diabetes, moderate to severe obstructive sleep apnea or noncirrhotic MASH with moderate to advanced fibrosis, and patients with Part D GLP-1 use in the period CMS reviews, which is calendar 2026 for now and not yet set for 2027. If members want to stay HSA-eligible, the drug itself has to sit outside the membership fee.

This guide is written for physicians and owners running a practice, and it is general information, not medical or legal advice. Every clinical detail below comes from a label, an agency page or the one cited trial, checked on November 5, 2026, and these pages have changed several times this year, so read the linked source again before you rely on it.

We looked for a survey of how DPC practices run GLP-1 care and found none. The membership ideas near the end are design options to think through, not benchmarks from other clinics.

Which GLP-1 drugs are FDA-approved for weight management?

Three products have a current weight-management indication worth planning around, and each label says the drug is used alongside a reduced-calorie diet and increased physical activity. This table comes from the current Wegovy label, Zepbound label and Foundayo label, and it is current as of today's check.

FDA also approved a 7.2 mg Wegovy dose on March 19, 2026, and noted more frequent reports of altered skin sensation at that dose. The Zepbound label says not to combine it with another tirzepatide product or any GLP-1 receptor agonist, and FDA says the same about Foundayo and other GLP-1 drugs.

Do controlled substance telehealth rules apply?

None of the three current labels we read carries a DEA schedule, so the federal rules on prescribing controlled substances by telehealth are not what governs these prescriptions. State licensure, your board's rules on establishing a patient relationship and the standard of care still apply, so check with your own board if you see members across state lines.

What are the rules on compounded semaglutide and tirzepatide?

Compounding is still legal under defined conditions, but the room is small and FDA has been narrowing it. FDA's statement to compounders, most recently updated April 1, 2026, says tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's shortage list. FDA's safety page adds that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.

Pharmacies and physicians under 503A

Section 503A covers state-licensed pharmacies and physicians who compound for an individual patient on a prescription. They cannot compound regularly or in inordinate amounts anything that is essentially a copy of a commercially available drug. FDA considers a product essentially a copy when it has the same active ingredient in the same, similar or easily substitutable strength and can be used by the same route.

The exception that matters to a prescriber is a documented determination that the compounded product contains a change that produces a significant difference for an identified individual patient. FDA also gives an example aimed directly at a common product. A compounded semaglutide with vitamin B12 may still count as a copy when it is given the same way and both ingredients are within 10% of the strengths of commercially available products. FDA has said it does not, at this time, intend to act against a compounder who fills four or fewer prescriptions of such a product in a calendar month.

Outsourcing facilities under 503B

Outsourcing facilities generally cannot compound from a bulk substance unless it is on the 503B bulks list or the drug is on the shortage list. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from that list, finding no clinical need, and it later extended the comment period to July 30, 2026. We did not find a final notice in the Federal Register today, so treat it as pending and check again.

What else FDA has flagged

In a February 6, 2026 statement, FDA said it intends to restrict GLP-1 ingredients used in mass-marketed compounded drugs, and that promotional materials cannot claim a compounded product is a generic version, is the same as an approved drug or uses the same active ingredient. If your website or member emails mention compounded options, check that language. FDA's safety page lists further concerns:

• Retatrutide and cagrilintide cannot be used in compounding under federal law, and neither is a component of an FDA-approved drug.
• FDA recommends discarding multiple-dose vials within 28 days of first use, even if the compounder's instructions say otherwise.
• FDA has complaints of injectable products arriving warm, and it recommends not using them.
• FDA reports hospitalizations that may be related to dosing errors with compounded semaglutide, some from clinicians miscalculating doses.
• Fraudulent products have carried the names of pharmacies that do not exist or did not make them.

If you dispense anything yourself, your state's rules apply on top of all of this. Our guide to DPC dispensing and labs covers how those rules work.

Is there still a GLP-1 shortage in 2026?

Not for the main weight-management injectables. We queried FDA's shortage data on November 5, 2026, and it returned no entries for tirzepatide, dulaglutide or semaglutide injection. The only semaglutide rows were three Rybelsus tablet strengths marked to be discontinued.

Liraglutide injection is the exception. It remains listed as a current shortage, with generic presentations shown as available and Saxenda and Victoza shown as limited availability. A separate Saxenda row marks it to be discontinued, updated August 25, 2026, so a patient still on it needs a plan. One generic row is also marked to be discontinued. FDA's drug shortages page is where to check before you act on any of this.

No listing does not mean every pharmacy has every strength. When FDA resolved the tirzepatide shortage, it noted that patients and prescribers may still see intermittent localized disruptions as product moves through the supply chain.

What monitoring do the GLP-1 labels call for?

The labels set safety checks, not a visit calendar. We did not find a required lab panel or follow-up interval in them beyond the titration steps, so the cadence below the safety items is your clinical judgment. These points come from the Wegovy, Zepbound and Foundayo labels as of today's check.

• Thyroid. All three carry a boxed warning on thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. All three labels say routine calcitonin or thyroid ultrasound monitoring is of uncertain value.
• Glucose. In patients with diabetes, monitor blood glucose before starting and during treatment.
• Kidneys. Monitor renal function in patients reporting adverse reactions, such as gastrointestinal ones, that could lead to volume depletion, especially during initiation and dose escalation.
• Eyes. Monitor patients with a history of diabetic retinopathy for progression.
• Heart rate. The Wegovy label says to monitor heart rate at regular intervals.
• Pregnancy. All three labels warn of possible fetal harm and say to stop when pregnancy is recognized, except that Wegovy for MASH may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The Wegovy label says to stop at least 2 months before a planned pregnancy when used for weight or cardiovascular risk, or for MASH where the potential risk outweighs the potential benefit, and the Foundayo label says to advise effective contraception during treatment.
• Oral contraceptives. The Zepbound label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase, and the Foundayo label says the same for 30 days.
• Other warnings to screen for. All three labels also address pancreatitis, gallbladder disease and pulmonary aspiration during anesthesia or deep sedation.

One older warning has come off. In a January 13, 2026 safety communication, FDA asked makers to remove suicidal behavior and ideation language after its review found no increased risk, and the current Wegovy and Zepbound labels show it removed.

Lifestyle support and long-term use

The USPSTF's recommendation on obesity in adults, dated September 18, 2018, gives a B grade to offering or referring adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions. Most of the intensive programs it reviewed ran 1 to 2 years, and the majority had 12 or more sessions in the first year. That recommendation is about behavioral care, and its drug trials predate the current products, so it does not settle how to use these medicines.

Length of treatment needs a real conversation at the start. In the SURMOUNT-4 trial in JAMA, adults who lost a mean of 20.9% on tirzepatide over 36 weeks then either continued or switched to placebo. From week 36 to week 88, those continuing lost a further 5.5%, and those on placebo regained 14%. That is one randomized trial of one drug, with authors from its maker, but it supports planning for long-term care and for what happens if a patient stops, including when coverage ends.

How do Medicare and Medicaid cover GLP-1s for weight loss in 2027?

CMS made two moves that matter for 2027. It extended the Medicare GLP-1 Bridge through December 31, 2027 and delayed the Part D portion of its BALANCE Model for calendar 2027, pending more data. The Bridge began July 1, 2026 and runs outside the Part D benefit. The eligible products are Foundayo, Wegovy injection and tablets, and the Zepbound KwikPen, when used for weight management.

CMS sets the beneficiary copay at $50 a month, with no deductible, no credit toward the true out-of-pocket total and no low-income subsidy. CMS's FAQ for plans puts the net price at $245 per monthly supply.

Who qualifies for the Medicare GLP-1 Bridge?

CMS's criteria require an eligible Part D plan type, age 18 or older, current and ongoing lifestyle modification including structured nutrition and physical activity, and one of these, measured when therapy began:

• BMI of 35 or higher.
• BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension as CMS defines it, or chronic kidney disease stage 3a or above.
• BMI of 27 or higher with prediabetes, previous myocardial infarction, previous stroke or symptomatic peripheral artery disease.

The reason for the prescription does not decide the route by itself. CMS says a patient diagnosed with type 2 diabetes, moderate to severe obstructive sleep apnea or noncirrhotic MASH with moderate to advanced fibrosis, which Part D covers, is not eligible for the Bridge, even on a weight-management prescription that meets the criteria above, and that a request attesting one of those diagnoses will be denied. A patient currently receiving a GLP-1 through Part D is not eligible either. For 2026, neither is a patient who received one through Part D in 2026, and CMS says it has not yet determined the lookback period it will apply during 2027. CMS tells prescribers to send any GLP-1 request for these patients to the Part D plan. Established cardiovascular disease is different. CMS does not make the physician attest that it is absent, but a prescription meant to reduce cardiovascular risk goes to the Part D plan. The table below sets out each route:

What the prior authorization looks like for a DPC physician

A useful point for a practice outside insurance is that CMS says a provider does not need to be enrolled in Medicare to prescribe or submit a prior authorization under the Bridge, as long as the provider is not on the Preclusion List. That FAQ does not use the words opted out, but 42 CFR 405.425(i) lets an opted-out physician who is not excluded, and whose Medicare enrollment has not been revoked, prescribe Medicare-covered drugs, provided the physician is not paid, directly or indirectly, for what they order, prescribe or refer, except as 42 CFR 405.440 allows. See our guides to opting out of Medicare and DPC for seniors on Medicare.

The order of steps is unusual, so write it down for your team:

1. Send the prescription first. CMS says a prior authorization submitted before a pharmacy claim exists returns "patient not found."
2. Wait for the request, which reaches you electronically or by fax, typically within 24 to 72 hours. After 72 hours you can download the fax form and submit it yourself.
3. Complete the form, which you attest to under penalty of perjury. CMS says it may check answers, such as a type 2 diabetes diagnosis, against Medicare data.
4. Expect a decision within 72 hours. There is no appeals process, though you can resubmit with corrected or added information.

Medicaid and commercial plans

Medicaid is state by state. The BALANCE Model lets state agencies that applied by July 31, 2026 start by January 1, 2027, and CMS says it will not guarantee coverage for any individual. The CMS page we read today does not list participating states, so ask your state's Medicaid agency rather than assuming.

We found no CMS statement on what happens to Bridge patients after December 31, 2027. For commercial plans, we did not find an agency source to quote, so check each member's own pharmacy benefit. A membership does not change that benefit, and our guide to insurance that pairs with DPC explains how the two fit together.

How should a DPC membership structure GLP-1 care?

Keep the clinical work in the membership and the drug outside it, then decide how to price the extra clinical time. The legal anchor is IRS Notice 2026-5, which puts prescription drugs other than vaccines outside a qualifying DPC arrangement. Our DPC and HSA guide walks through the rule on prescription drugs.

The other limit is the fee cap, which counts all of a person's DPC fees together. IRS Rev. Proc. 2026-24 keeps it at $150 a month for one person and $300 for a membership covering more than one.

Here are three shapes to weigh with your tax adviser:

The trap in the third option is the rule in Q-11. Billing members separately for care that comes with the membership can cost the arrangement its status, so write down clearly which work belongs to which product. Separately billed self-pay items can also bring good faith estimate questions, and a higher tier changes your pricing math.

Planning for the extra work

We found no published data on how much time GLP-1 care adds to a DPC panel, so measure your own. Titration alone means a decision point every 4 weeks or 30 days during the first months, and the labels add contraception counseling, renal checks when symptoms appear and a pre-anesthesia conversation. Add that time to your panel size math rather than assuming it fits. A member who loses coverage also needs a plan with you, which touches retention too.

The hard part is follow-through across tools. The next dose step sits in the chart, the Bridge request arrives by fax, the side-effect message lands in your inbox, and the coverage answer comes by mail to the patient. Tabflows is a dedicated tech team that connects the tools a clinic already uses, so a task like "follow-up labs due" or "prior authorization still open" lands in one place with the patient's context attached. It does not replace your EHR, billing or messaging, and the clinical decisions stay yours.

The bottom line for 2027

Titration and side-effect questions are the kind of work direct access is built for, and the parts to get right sit outside the exam room. Use approved products unless you can document why a patient's need requires something else, confirm shortage and 503B status on FDA's pages before you act, route Medicare patients by their diagnoses, any Part D GLP-1 fill in CMS's lookback period and the reason for the prescription, and keep the drug outside the fee.

Three things could still change, namely FDA's final decision on the 503B list, CMS's 2027 lookback period for Part D GLP-1 use and what follows the Bridge after its end date. If you are building this into a new practice, our guide to starting a DPC and the related piece on chronic disease management in DPC are good next reads.